Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Structural basis for inhibition of protein tyrosine phosphatases by Keggin compounds phosphomolybdate and phosphotungstate
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 July 2002

Structural basis for inhibition of protein tyrosine phosphatases by Keggin compounds phosphomolybdate and phosphotungstate

  • Yong-Seok Heo1,
  • Jung Min Ryu,
  • Sang Myun Park,
  • Jeon Han Park,
  • Hyun-Chul Lee,
  • Kwang Yeon Hwang &
  • …
  • Jong Sun Kim 

Experimental & Molecular Medicine volume 34, pages 211–223 (2002)Cite this article

  • 1196 Accesses

  • 31 Citations

  • Metrics details

Abstract

Protein-tyrosine phosphatases (PTPs) constitute a family of receptor-like, and cytoplasmic enzymes, which catalyze the dephosphorylation of phosphotyrosine residues in a variety of receptors and signaling molecules. Together with protein tyrosine kinases (PTKs), PTPs are critically involved in regulating many cellular signaling processes. In this study, diverse compounds were screened for PTP inhibition and selectively screened for inhibitors with the end product inhibition properties. Among phosphate analogues and their derivatives for PTP inhibition, Keggin compounds phosphomolybdate (PM) and phosphotungstate (PT) strongly inhibited both PTP-1B and SHP-1, with K(i) values of 0.06-1.2 µM in the presence of EDTA. Unlike the vanadium compounds, inhibition potencies of PM and PT were not significantly affected by EDTA. PM and PT were potent, competitive inhibitors for PTPs, but relatively poor inhibitors of Ser/Thr phosphatase. Interestingly, PM and PT did not inhibit alkaline phosphatase at all. The crystal structure of PTP-1B in complex with PM, at 2.0 A resolution, reveals that MoO(3), derived from PM by hydrolysis, binds at the active site. The molybdenium atom of the inhibitor is coordinated with six ligands: three oxo-ligands, two apical water molecules and a S atom of the catalytic cysteine residue. In support of the crystallographic finding, we observed that molybdenium oxides (MoO(3), MoO(2), and MoO(2)Cl(2)) inhibited PTP-1B with IC(50) in the range 5-15 µM.

Similar content being viewed by others

The catalytic activity of TCPTP is auto-regulated by its intrinsically disordered tail and activated by Integrin alpha-1

Article Open access 10 January 2022

Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders

Article 24 January 2023

Protein tyrosine phosphatases in skeletal development and diseases

Article Open access 28 January 2022

Article PDF

Author information

Authors and Affiliations

  1. CrystalGenomics, Inc., Taejeon, Korea

    Yong-Seok Heo

Authors
  1. Yong-Seok Heo
    View author publications

    Search author on:PubMed Google Scholar

  2. Jung Min Ryu
    View author publications

    Search author on:PubMed Google Scholar

  3. Sang Myun Park
    View author publications

    Search author on:PubMed Google Scholar

  4. Jeon Han Park
    View author publications

    Search author on:PubMed Google Scholar

  5. Hyun-Chul Lee
    View author publications

    Search author on:PubMed Google Scholar

  6. Kwang Yeon Hwang
    View author publications

    Search author on:PubMed Google Scholar

  7. Jong Sun Kim
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Heo, YS., Ryu, J., Park, S. et al. Structural basis for inhibition of protein tyrosine phosphatases by Keggin compounds phosphomolybdate and phosphotungstate. Exp Mol Med 34, 211–223 (2002). https://doi.org/10.1038/emm.2002.30

Download citation

  • Published: 01 July 2002

  • Issue date: 01 July 2002

  • DOI: https://doi.org/10.1038/emm.2002.30

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • Protein-tyrosine-phosphatase
  • molybdenum
  • tungsten compounds
  • enzyme inhibitors
  • crystallography

This article is cited by

  • The interactions of metal cations and oxyanions with protein tyrosine phosphatase 1B

    • Kshetrimayum Birla Singh
    • Wolfgang Maret

    BioMetals (2017)

  • Kinetics of Inhibition of Rabbit Intestine Alkaline Phosphatase by Heteroligand Peroxo Complexes of Vanadium(V) and Tungsten(VI)

    • Diganta Kalita
    • Siva Prasad Das
    • Nashreen S. Islam

    Biological Trace Element Research (2009)

  • New peroxovanadium compounds containing biogenic co-ligands: synthesis, stability and effect on alkaline phosphatase activity

    • Pankaj Hazarika
    • Swapnalee Sarmah
    • Nashreen S. Islam

    Transition Metal Chemistry (2008)

  • New oxo-bridged peroxotungsten complexes containing biogenic co-ligand as potent inhibitors of alkaline phosphatase activity

    • Pankaj Hazarika
    • Diganta Kalita
    • Nashreen s. Islam

    Molecular and Cellular Biochemistry (2006)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited